1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
AI Accelerator Grant Program (Ovarian Cancer Research) is sponsored by Ovarian Cancer Research Alliance (OCRA). This opportunity supports mission-aligned projects and measurable outcomes.
Get alerted about grants like this
Save a search for “Ovarian Cancer Research Alliance (OCRA)” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Ovarian Cancer Research Grant Programs | OCRA Ovarian Cancer Research Grant Programs OCRA’s Schreiber Research Grants Program supports gifted scientists at every stage of their careers, including postdoctoral fellows, early-career independent investigators, and teams of experienced investigators.
Championing the Most Promising Research OCRA has awarded over 400 grants to top scientists at 100 leading medical centers around the world, enabling a series of discoveries that have accelerated our journey toward a cure. All of our grants involve a rigorous review process to ensure that only the most outstanding research projects are funded.
The Global Ovarian Cancer Research Consortium, comprising Ovarian Cancer Research Alliance (OCRA, USA), Ovarian Cancer Action (OCA, UK), Ovarian Cancer Canada (OCC), and The Ovarian Cancer Research Foundation (OCRF, Australia), provides a $1 million USD grant, along with AWS compute support, to power research that aims to improve ovarian cancer survival rates.
This grant was introduced in 2025 in partnership with Microsoft’s AI for Good Lab and now provides in-kind cloud compute credits from Amazon Web Services (AWS). This grant supports international, multidisciplinary research using artificial intelligence (AI) to improve ovarian cancer survival rates.
Proposals must include lead investigators from the United States, United Kingdom, Canada, and Australia, and must demonstrate significant AI integration. Support of up to $1 million USD to be used over 3 years, will be awarded to the institution of the Principal Investigator.
Collaborative Research Development Grant Launched in 2004, this grant provides funds for research projects focusing on ovarian cancer and/or related gynecologic cancer research, that involve several investigators within one institution or collaborations between groups in multiple institutions.
Support of $300,000 annually for three years, for a total of $900,000, will be awarded to the institution where the recipient will conduct the research. Collaborative Research Development Grant – Microsoft's AI for Good Lab Launched in 2022, this grant is the result of a unique partnership between OCRA and Microsoft’s AI for Good Lab, a philanthropic program at Microsoft.
This collaboration will help OCRA accelerate ovarian cancer and/or related gynecologic cancer research by harnessing the power of data science and Artificial Intelligence (AI), potentially leading to new insights into the disease.
The grant will provide funds for ovarian cancer and/or related gynecologic cancers research projects that may involve several investigators within one institution or collaborations between groups in multiple institutions. Support of $300,000 annually for three years, for a total of $900,000, will be awarded to the institution where the recipient will conduct the research in addition to in-kind support from Microsoft.
Early Career Investigator Grant The Early Career Investigator Grant (formerly the Liz Tilberis Early Career Award) is for junior faculty (Assistant Professor level) with a strong commitment to an investigative career in ovarian cancer and/or related gynecologic cancer research. Support of $150,000 annually for three years, for a total of $450,000, will be awarded to the institution where the recipients will conduct the research.
This grant was created in honor of Liz Tilberis, former editor-in-chief of Harper’s Bazaar and the first president of Ovarian Cancer Research Alliance, who passed away from ovarian cancer in 1999.
Mentored Investigator Grant The Mentored Investigator Grant (formerly the Ann and Sol Schreiber Mentored Investigator Award) provides funding for trainees (post-doctoral fellows or clinical fellows) working under the supervision of a mentor who is a recognized leader in ovarian cancer research, or related area. Applicants must have an MD or a PhD degree.
The grant provides a total of $100,000 to be used over one or two years and will encourage the recipient’s research career in the field of ovarian cancer and/or related gynecologic cancers. Ann Schreiber, a distinguished public administrator and wife of Ovarian Cancer Research Alliance’s founder Sol Schreiber, is the inspiration for this grant. Sol started OCRA in memory of Ann, who passed away from ovarian cancer in 1994.
Health Equity Research Grant OCRA’s first-ever Health Equity Research Grant (HEG) was launched in 2024. The first grant was sponsored by GSK. This grant is intended to overcome barriers to care faced by marginalized communities and is geared to all investigators with projects focusing on ovarian cancer and/or related gynecologic cancers research that have a health equity focus.
Support of $100,000 annually for two years, for a total of $200,000, will be awarded to the institution where the recipient will conduct the research. The Rivkin Pilot Grants pave the way for innovative breakthroughs in all areas of ovarian cancer research. Support of $50,000 annually for 2 years, totaling $100,000,* will be awarded to the institution where the recipient will conduct the research.
The grants were inspired by Marsha Rivkin, beloved wife of Dr. Saul Rivkin, a renowned oncologist at Swedish Hospital. After her death from ovarian cancer, Dr. Rivkin and his daughters established the Marsha Rivkin Ovarian Cancer Research Center, which eventually became the Seattle-based Rivkin Center. OCRA and the Rivkin Center joined forces in a historic collaboration in April 2025, enhancing OCRA’s national and global reach.
OCRA is proud to be continuing the Rivkin Center’s extraordinary legacy of hope, determination, and relentless pursuit of a cure through its Rivkin Pilot Grants. *Prior to 2027 funding cycle, this grant provided $75,000 over 2 years.
The Rivkin Center and Washington state’s Andy Hill Cancer Research Endowment (CARE) Fund joined together to invest $1M in ovarian cancer research in 2024 and 2025, creating a pioneering public-private partnership. Investigators in Washington state pursuing projects in all areas of ovarian cancer research were eligible to apply to these two-year awards.
Researchers did not need to find additional funding as the Rivkin Center and the CARE Fund matched private and state funds 1:1. Past Rivkin Center Grantees The Rivkin Center for Ovarian Cancer Research offered research grants from 1999 to 2025. In addition to the Rivkin Pilot Grant, which OCRA is continuing, Rivkin offered funds for 2 other grants: Scientific Scholar Awards and Bridge Funding Awards.
The Scientific Scholar Award was a two-year mentored career development grant of up to $120,000 for early researchers pursuing a career as an independent investigator. The Bridge Funding Award was a six-month grant for $30,000 which helped researchers gather the data needed to secure federal grants, allowing promising work to progress to the next stage.
OCRA-Funded ROCCA Platform Launches to Accelerate Rare Ovarian Cancer Research OCRA is proud to announce the launch of the Rare Ovarian Cancer Collaborative Analytics (ROCCA) Platform, an international federated data network funded by OCRA to connect researchers globally and accelerate breakthroughs in rare ovarian cancer research.
A collaborative approach to research for rare ovarian cancer ROCCA is launching with two foundational projects: one in mucinous … Continued We’re Changing How Cancer Research Happens We Believe There’s a Better Way to Do Research So we created it. OCRA has launched the most ambitious initiative in our history.
We believe it represents a fundamentally new way for research to work—one with the potential to accelerate discovery in gynecologic cancers while serving as a model for breakthroughs across all diseases.
We … Continued Ovarian Cancer Research Alliance Launches Community Accelerated Research Exchange, a Global AI-Powered Ecosystem to Transform Gynecologic Cancer Research Platform, powered by AWS, connects patients, researchers, and clinicians to accelerate breakthroughs in gynecologic cancers [NEW YORK, NY – May 8, 2026] — Ovarian Cancer Research Alliance (OCRA) today announced the launch of the Community Accelerated Research Exchange, a first-of-its-kind, global, AI-powered ecosystem designed to transform how gynecologic cancer research is conducted—accelerating breakthroughs by connecting … Continued Introducing the Community Accelerated Research Exchange A global, Al-powered ecosystem designed to transform gynecologic cancer research—connecting patients, researchers, and clinicians to accelerate breakthroughs.
Continue to Research Exchange c. startsWith(this. consentName + '=')); this.
isVisible = ! this. hasConsent(); // 1 year expiry; SameSite=Lax + Secure for sane defaults.
const oneYear = 60 * 60 * 24 * 365; x-transition. opacity. duration.
300ms class="pointer-events-none fixed bottom-0 left-0 px-6 pb-6"
Based on current listing details, eligibility includes: Minimum of 4 senior lead investigators; required representation from various fields relevant to the research. Emphasizes interdisciplinary research teams. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Up to $1,000,000 over 3 years for PI's institution; up to $200,000 per year additional support; up to $600,000 total in AWS cloud compute credits Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is June 23, 2026. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.